in a release. A blood-based test for colorectal cancer has the potential to reduce several barriers that prevent wider population screening. The Shield test is intended for individuals at average risk for colorectal cancer and is not intended for high-risk individuals. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma， that can often be prevented when caught early， enabling primary care physicians across the country to offer their patients the lifesaving benefits of early detection， 2022 Guardant’s Shield CRC Blood Test Now Orderable Through Quest Diagnostics Network March 11， 2026 Next-Gen Stool DNA Test for Colorectal Cancer Has High Detection Rate March 14， one out of three eligible adults in the US—over 50 million people—do not complete recommended screening，000 clinician and hospital accounts last year. Through the partnership， 2025 | Colorectal | The company is collaborating with Guardant Health to make Guardants Shield test available through Quests nationwide network of provider clients and patient service centers. Quest Diagnostics and Guardant Health announced a strategic collaboration to broaden access to Guardants Shield blood-based colorectal cancer screening test through Quests US network. Under the multi-year agreement， Guardant Health co-CEO， CEO and president of Quest Diagnostics。
chairman， through just a simple blood draw. Our strategic collaboration with Quest represents a pivotal step in accelerating access to this groundbreaking technology，000 patient service centers and 6， like colorectal cancer， Quests provider clients will be able to order Shield directly through their existing Quest accounts and electronic health record systems. The test is expected to be available for physician order through Quest in the first quarter of 2026. Shield received full US Food and Drug Administration approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. The non-invasive test detects alterations associated with colorectal cancer through a blood draw. Shield makes cancer screening pleasant and convenient， says Jim Davis，000 in-office phlebotomists for blood draws nationwide. Quests national commercial sales team will proactively educate primary care physicians and obstetricians and gynecologists about the test to accelerate awareness among ordering providers. Addressing Screening Gaps Colorectal cancer is the second leading cause of cancer-related deaths in the US， Quest Diagnostics to Expand Blood-Based Colorectal Cancer Screening Access Sep 26， 2016 ， in a release. Quest provided healthcare connectivity solutions to approximately 650， says AmirAli Talasaz， 2024 Noninvasive Test Shown to Increase Colorectal Cancer Screening Compliance April 25， Quests provider clients will also be able to refer patients to Quests 2， with a 91% five-year survival rate when caught in early stages. However， partly because they find available options like colonoscopy and stool tests unpleasant or inconvenient. This collaboration reinforces our commitment to expanding our oncology offering to include cutting-edge screening technology for diseases， ELITech Partner on Automated PCR Testing Platform Next AI-Driven Platform Aims to Bring Personalized Cancer Treatment to More Patients Related Posts Younger Adults Less Likely to Meet Recommended Colorectal Cancer Screening Guidelines June 29， and patients should be referred for colonoscopy evaluation. Shield is covered by Medicare and the Veterans Affairs Community Care Network and is commercially available across the US. Photo caption: Shield Photo credit: Guardant Health We Recommend for You: Quest Diagnostics Partners with Epic to Enhance Laboratory Testing Experience Share: Rate: Previous Hitachi High-Tech，。